Published in Stroke on June 02, 2005
Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2014) 3.48
Ischemic stroke in the elderly: an overview of evidence. Nat Rev Neurol (2010) 1.15
Risk factors for acute ischaemic stroke in young adults in South India. J Neurol Neurosurg Psychiatry (2007) 1.05
Metabolic syndrome increases the risk of stroke: a 5-year follow-up study in a Chinese population. J Neurol (2009) 1.00
Metabolic syndrome with hyperglycemia and the risk of ischemic stroke. Yonsei Med J (2013) 0.86
The case for an elderly targeted stroke management. Front Neurol (2011) 0.86
The metabolic syndrome among patients with cardiovascular disease in Accra, Ghana. Ghana Med J (2011) 0.83
Effects of prescription niacin and omega-3 fatty acids on lipids and vascular function in metabolic syndrome: a randomized controlled trial. J Lipid Res (2012) 0.82
Metabolic syndrome and the short-term prognosis of acute ischemic stroke: a hospital-based retrospective study. Lipids Health Dis (2015) 0.78
Hyperglycemia accelerates apparent diffusion coefficient-defined lesion growth after focal cerebral ischemia in rats with and without features of metabolic syndrome. J Cereb Blood Flow Metab (2013) 0.78
Evaluation of metabolic syndrome in patients with chronic low back pain: using the fourth Korea national health and nutrition examination survey data. Chonnam Med J (2011) 0.76
Metabolic Syndrome Is a Strong Risk Factor for Minor Ischemic Stroke and Subsequent Vascular Events. PLoS One (2016) 0.75
The Intricate Network of Adipokines and Stroke. Int J Endocrinol (2015) 0.75
Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA (2012) 9.37
Mean platelet volume: a link between thrombosis and inflammation? Curr Pharm Des (2011) 4.16
Kounis syndrome: a new twist on an old disease. Future Cardiol (2011) 2.51
Clinical review: The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. J Clin Endocrinol Metab (2009) 2.50
Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. Am Heart J (2004) 2.09
Clinical benefits of ezetimibe use: is absence of proof, proof of absence? Expert Opin Pharmacother (2012) 2.01
Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism (2006) 2.01
Clinical profile and therapeutic management of patients with atrial fibrillation in Greece: results from the Registry of Atrial Fibrillation to Investigate New Guidelines (RAFTING). Hellenic J Cardiol (2013) 1.98
Time for new indications for statins? Med Sci Monit (2009) 1.87
Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases. Br J Haematol (2005) 1.86
The hyponatremic patient: a systematic approach to laboratory diagnosis. CMAJ (2002) 1.67
High prevalence of autoimmune thyroiditis in schoolchildren after elimination of iodine deficiency in northwestern Greece. Thyroid (2003) 1.67
Atrial fibrillation and electrical remodeling: the potential role of inflammation and oxidative stress. Med Sci Monit (2003) 1.62
Orlistat-associated adverse effects and drug interactions: a critical review. Drug Saf (2008) 1.58
Incidence and predictors of delirium after cardiac surgery: Results from The IPDACS Study. J Psychosom Res (2010) 1.54
Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study. Curr Med Res Opin (2011) 1.53
The impact of smoking on cardiovascular outcomes and comorbidities in statin-treated patients with coronary artery disease: a post hoc analysis of the GREACE study. Curr Vasc Pharmacol (2013) 1.53
Comparison of the five 2011 guidelines for the treatment of carotid stenosis. J Vasc Surg (2012) 1.51
Is high-sensitivity C-reactive protein associated with subclinical peripheral atherosclerosis? Angiology (2009) 1.47
Atorvastatin: safety and tolerability. Expert Opin Drug Saf (2010) 1.47
Platelets as predictors of vascular risk: is there a practical index of platelet activity? Clin Appl Thromb Hemost (2003) 1.45
Colesevelam plus rosuvastatin 5 mg/day versus rosuvastatin 10 mg/day alone on markers of insulin resistance in patients with hypercholesterolemia and impaired fasting glucose. Metab Syndr Relat Disord (2012) 1.44
Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: the EVET trial. Am Heart J (2003) 1.43
The role of Toll-like receptors in renal diseases. Nat Rev Nephrol (2010) 1.42
Sevelamer hydrochloride versus aluminum hydroxide: effect on serum phosphorus and lipids in CAPD patients. Perit Dial Int (2006) 1.42
Beware of, not only the dogs, but the passionate kissing and the Kounis syndrome. J Cardiovasc Med (Hagerstown) (2011) 1.42
Lipoprotein (a) levels and apolipoprotein (a) isoform size in patients with subclinical hypothyroidism: effect of treatment with levothyroxine. Thyroid (2003) 1.40
Unexplained hypertransaminasaemia: clue to diagnosis of Addison's disease. Eur J Gastroenterol Hepatol (2002) 1.40
Association between epicardial fat thickness and weight homeostasis hormones in patients with noncachectic heart failure. Angiology (2012) 1.40
The effect of simvastatin alone versus simvastatin plus ezetimibe on the concentration of small dense low-density lipoprotein cholesterol in subjects with primary hypercholesterolemia. Curr Med Res Opin (2011) 1.39
Optimal statin type and dosage for vascular patients. J Vasc Surg (2011) 1.39
Multiple actions of high-density lipoprotein. Curr Opin Cardiol (2008) 1.39
Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin (2006) 1.38
Platelet activation in bypass surgery for critical limb ischemia. Vasc Endovascular Surg (2007) 1.38
CORONA, statins, and heart failure: who lost the crown? Angiology (2008) 1.38
Pheochromocytoma: an update on genetics and management. Endocr Relat Cancer (2007) 1.34
Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog Lipid Res (2012) 1.33
Adrenal incidentaloma: a diagnostic challenge. Hormones (Athens) (2009) 1.29
Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. Curr Vasc Pharmacol (2011) 1.27
Gender-related and age-related urinalysis of healthy subjects by NMR-based metabonomics. NMR Biomed (2008) 1.25
Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant (2006) 1.24
Elevated heart rate and atherosclerosis: an overview of the pathogenetic mechanisms. Int J Cardiol (2008) 1.23
The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitions. Curr Med Res Opin (2005) 1.22
The prevalence of metabolic syndrome in various populations. Am J Med Sci (2007) 1.19
Drug-induced fibrotic valvular heart disease. Lancet (2009) 1.19
Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia. Am J Cardiovasc Drugs (2010) 1.18
An overview of the extra-lipid effects of rosuvastatin. J Cardiovasc Pharmacol Ther (2008) 1.16
Evaluation of the effect of oxidative stress and vitamin E supplementation on renal function in rats with streptozotocin-induced Type 1 diabetes. J Diabetes Complications (2008) 1.14
The effect of statin therapy on arterial stiffness by measuring pulse wave velocity: a systematic review. Curr Vasc Pharmacol (2010) 1.14
Response to 'Red blood cell distribution width is a predictor of readmission in cardiac patients'. Clin Cardiol (2013) 1.14
Postoperative atrial fibrillation - what do we really know? Curr Vasc Pharmacol (2010) 1.14
Prevalence of vascular disease in metabolic syndrome using three proposed definitions. Int J Cardiol (2006) 1.12
IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis. Arch Med Sci (2011) 1.12
Platelet function in rheumatoid arthritis: arthritic and cardiovascular implications. Rheumatol Int (2011) 1.12
Vascular risk factors in South Asians. Int J Cardiol (2008) 1.11
Prediabetes: to treat or not to treat? Eur J Pharmacol (2011) 1.11
Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis (2004) 1.11
Metformin and cancer. Eur J Pharmacol (2013) 1.11
The rationale for comparative studies of accelerated atherosclerosis in rheumatic diseases. Curr Vasc Pharmacol (2010) 1.10
HSP 70 and atherosclerosis--protector or activator? Expert Opin Ther Targets (2009) 1.10
Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients. Liver Int (2011) 1.10
Eosinophilic responses to stent implantation and the risk of Kounis hypersensitivity associated coronary syndrome. Int J Cardiol (2011) 1.09
Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients. Am J Cardiol (2007) 1.09
Variable effects of statins on glucose homeostasis parameters and their diabetogenic role. Diabetologia (2015) 1.08
Lone atrial fibrillation: what do we know? Heart (2009) 1.08
Frequency of inappropriate and nonrecommended prasugrel prescription: great variations. J Am Coll Cardiol (2014) 1.08
Clinical relevance of postprandial lipaemia. Curr Med Chem (2005) 1.08
Pleiotropic effects of statins--clinical evidence. Curr Pharm Des (2009) 1.08
The effect of smoking on arterial stiffness. Hypertens Res (2010) 1.07
Multiple cerebral mycotic aneurysms due to left atrial myxoma: are there any pitfalls for the cardiac surgeon? Hellenic J Cardiol (2011) 1.07
Comment to "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property". Dig Liver Dis (2012) 1.06
Statins: a sine qua non of the management of patients with abdominal aortic aneurysms. Int J Cardiol (2013) 1.06
Serum uric acid as an independent predictor of early death after acute stroke. Circ J (2007) 1.06
Evaluation of methods for the measurement of low-density lipoprotein cholesterol. J Cardiovasc Pharmacol Ther (2005) 1.05
Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality. Expert Opin Drug Saf (2008) 1.05
An update on biomarkers of heart failure in hypertensive patients. J Hypertens (2012) 1.04
Epicardial fat and vascular risk: a narrative review. Curr Opin Cardiol (2013) 1.04
The mechanisms of atrial fibrillation in hyperthyroidism. Thyroid Res (2009) 1.03
Ghrelin can bind to a species of high density lipoprotein associated with paraoxonase. J Biol Chem (2003) 1.03
Visfatin/PBEF and atherosclerosis-related diseases. Curr Vasc Pharmacol (2010) 1.03
Awareness, treatment and control of the metabolic syndrome and its components: a multicentre Greek study. Hellenic J Cardiol (2006) 1.02
Vitamin D and metabolic syndrome: is there a link? Curr Pharm Des (2010) 1.02
Intramural haematoma of the thoracic aorta: who's to be alerted the cardiologist or the cardiac surgeon? J Cardiothorac Surg (2009) 1.02
Statins and cardiovascular outcomes in elderly and younger patients with coronary artery disease: a post hoc analysis of the GREACE study. Arch Med Sci (2013) 1.01
Comparison of four definitions of the metabolic syndrome in a Greek (Mediterranean) population. Curr Med Res Opin (2010) 1.01
What should be the optimal levels of blood pressure: Does the J-curve phenomenon really exist? Expert Opin Pharmacother (2011) 1.01
Dyslipidemia in patients with thyroid disorders. Hormones (Athens) (2006) 1.01
Emerging indications for statins: a pluripotent family of agents with several potential applications. Curr Pharm Des (2007) 1.01
Should adipokines be considered in the choice of the treatment of obesity-related health problems? Curr Drug Targets (2010) 1.01
Liver enzymes: potential cardiovascular risk markers? Curr Pharm Des (2011) 1.01
Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. Expert Opin Biol Ther (2007) 1.01
Metformin and cancer: licence to heal? Expert Opin Investig Drugs (2010) 1.01